

September 21, 2017

**Otsuka Pharmaceutical Factory completes acquisition of
additional equity in its joint venture subsidiary,
Otsuka Pharmaceutical India Private Limited**

Otsuka Pharmaceutical Factory, Inc. (OPF) today completed the acquisition of the outstanding shares held by Claris Lifesciences Limited* in Otsuka's Indian joint venture subsidiary, Otsuka Pharmaceutical India Private Limited (Otsuka India). Accordingly, OPF now holds 80% of the outstanding equity shares of Otsuka India and Mitsui & Co., Ltd. holds the remaining 20% .

*The agreement for the acquisition of the Claris shares was announced on May 8, 2017, "Otsuka Pharmaceutical Factory enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited (OPI)".

Company Profile

Otsuka Pharmaceutical India Private Limited

Date of Establishment : July 31, 2013
of the Joint Venture
Capital : 10.524 billion INR (approximately 17.9 billion JPY)
Investment Ratio : (Before Share Transfer) OPF: 60%, Claris: 20%, Mitsui: 20%
(After Share Transfer) OPF: 80%, Mitsui: 20%
Representative : Shuichi Takagi, CEO
Head office : Ahmedabad, Gujarat, India
Employees : 1,059 (as of December 31, 2016)
Scope of Business : Manufacture and distribution of basic IV solutions and clinical nutrition products
Business Area : India and over 50 countries worldwide
Website (URL) : <http://www.otsukapharma.in/>

Otsuka Pharmaceutical Factory, Inc.

Established : October 7, 1969
Capital : 80 million yen
Representative : Shinichi Ogasawara, President and Representative Director
Head office : 115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima, Japan
Employees : 2,309 (as of December 31, 2016)
Scope of Business : Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, and functional foods, etc.
Website (URL) : <http://www.otsukakj.jp/en/>